Our History

 Track and record of
 success in oncology

Accelera was born

AAALAC Accreditation

Accelera is selected for inclusion within the European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL), established by the EU Commission

Collaboration with Medicine for Malaria Venture, for antimalarial drugs in order to select those with the least toxic effect possible

Collaboration with Karolinska development

Collaboration with Cellectis to complete preclinical studies of Cellectis’ lead product cadidate UCART19

Starting activity with CAR-T cells

– Efficacy models
– Pilot studies for cell engrafment, tolerability, surgical implantation
– GLP cell fate/biodistribution by FACS analysis
– GLP safety (toxicology)
– GLP tumorigenicity
– Pathology and necropsy
– Immunohistochemistry, qPCR/ddPCR

Headline news: Gene therapy saves a 1-year-old girl from leukemia

Collaboration with the Politecnico of Milan for the development of organ-on-chip technology on cardiomyocytes

Proud to be among DNI partners

DNDi and partners developed a breakthrough treatment for sleeping sickness